Physician profile
Yvan Tranquille
NPI 1134573827
$601.79
in general payments reported to CMS, 2019-2025
10 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.10 · 2023: $38.33 · 2024: $124 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $225.27 | 2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2025 | Breztri |
| Exact Sciences Corporation | $112.65 | 2023-2025 | Cologuard Collection Kit |
| Qiagen, LLC | $23.59 | 2024 | |
| Inari Medical, INC. | $22.22 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $21.77 | 2023 | Bexsero |
| Merck Sharp & Dohme LLC | $19.47 | 2024 | M-M-R II, Varivax, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.81 | 2024 | Xifaxan |
| Alkermes, INC. | $18.10 | 2021 | |
| Lilly USA, LLC | $18.08 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvan Tranquille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.